Crossmark

An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis

Crossref DOI link: https://doi.org/10.1007/s40263-018-0496-6

Published Online: 2018-03-05

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vaughn, Caila

Bushra, Aisha

Kolb, Channa

Weinstock-Guttman, Bianca
Funding

Funding for this research was provided by:

Teva Pharmaceuticals
License Information

Text and Data Mining valid from 2018-02-01
More Information

Article History

First Online: 5 March 2018

Compliance with Ethical Standards

:

: Dr. Vaughn has nothing to disclose. Dr. Bushra has nothing to disclose. Dr. Kolb has received speaker honoraria and consultant fees from EMD Serono, Teva Pharmaceuticals, Acorda, Novartis, Genzyme, and Biogen-Idec. Dr. Weinstock-Guttman has received consultancy fees, honoraria, and research support from Teva Neuroscience, Biogen Idec, EMD Serono, Novartis, Genentech, Sanofi Genzyme, and Mallinckrodt. She has also participated in advisory boards for Teva Neuroscience, Biogen Idec, EMD Serono, Novartis, Genentech, and Sanofi Genzyme, and received honoraria for speaking from Teva Neuroscience, Biogen Idec, EMD Serono, Novartis, Genentech, and Sanofi Genzyme.